R45
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.300
- WNT_BETA_CATENIN_SIGNALING+0.270
- NOTCH_SIGNALING+0.260
- CHOLESTEROL_HOMEOSTASIS+0.220
- PEROXISOME+0.220
- DNA_REPAIR+0.190
- UNFOLDED_PROTEIN_RESPONSE+0.190
- APICAL_SURFACE+0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.130
- ESTROGEN_RESPONSE_EARLY+0.110
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.480
- INTERFERON_GAMMA_RESPONSE-0.390
- IL6_JAK_STAT3_SIGNALING-0.380
- ANDROGEN_RESPONSE-0.350
- UV_RESPONSE_DN-0.320
- COMPLEMENT-0.310
- PROTEIN_SECRETION-0.310
- INTERFERON_ALPHA_RESPONSE-0.280
- KRAS_SIGNALING_UP-0.280
- HEDGEHOG_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R22 | — | — | 0.840 |
| 2 | DRR168523 | — | — | 0.803 |
| 3 | R3 | — | — | 0.766 |
| 4 | 5d2d4263-d17d-424f-9c82-bf665306d71f | — | — | 0.759 |
| 5 | TCGA-B6-A0X0-01A-21R-A115-07 | — | B | 0.755 |
| 6 | 5cfccf66-7f7d-4385-96c8-8628a3cdbecb | — | — | 0.751 |
| 7 | SJEPD037_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.750 |
| 8 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.746 |
| 9 | SRR25043618 | — | — | 0.739 |
| 10 | 63bab58e-1dfd-43df-8188-4b8d766913f3 | — | — | 0.738 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |